(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
All that You Really want to Be aware of Dental Inserts Facilities - 2Pedal Power: Divulging Well known Bike Brands for Each Cyclist
- 3Investigating Inside Plan and Home Style: Change Your Residing Space
- 4UN panel says Israel operating 'de facto policy of torture'
- 5US FDA declines to approve Corcept's drug for rare hormonal disorder
- 10 Famous Frozen yogurt Flavors All over The Planet
- Find the Historical backdrop of Common liberties: Advancing Equity and Equity Around the world
- Sound Maturing: Wellbeing Tips for Each Life Stage
- Ariana Grande says Eternal Sunshine 2026 tour will be her last for a 'long, long time': 'One last hurrah'
- Volkswagen Plant Could Pivot From Building Cars to Supporting Iron Dome Systems
- Vote in favor of your #1 Kind of Cap
- These Cities Led Global Jet-Setting In 2025, According To New Data
- Interstellar comet 3I/ATLAS isn't an alien spacecraft, astronomers confirm. 'In the end, there were no surprises.'
- Africa's energy giants eye long-term gains on Iran war disruption
